KPTI News and Press, Karyopharm Therapeutics Inc. From 04/26/21

Karyopharm Announces European Medicines Agency's Validation of its Type II Variation Marketing Authorization Application for NEXPOVIO® (selinexor) in Combination with Velcade® (bortezomib) and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma - EM...

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) traded today at $9.34, breaking its 52-week low. So far today approximately 720,000 shares have been exchanged, as compared to an average 30-day volume of 1.9 million shares. Karyopharm Therapeutics Inc is a pharmaceutical company. The...

Karyopharm Announces Publication of Health-Related Quality of Life Outcomes from Phase 3 SEAL Study of Selinexor in Advanced Unresectable Dedifferentiated Liposarcoma in Future Oncology - Treatment with Selinexor Demonstrated Several Potential Clinical Advantages Compared to Pla...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) traded at a new 52-week low today of $9.73. So far today approximately 720,000 shares have been exchanged, as compared to an average 30-day volume of 2 million shares. Karyopharm Therapeutics Inc. has overhead space with shares priced $9.81, or ...

Gainers: [[GLYC]] +3.5%. [[CBAY]] +2.6%. [[KPTI]] +2.6%. [[GMAB]] +2.5%. [[SYRS]] +2.4%.Losers: [[VECT]] -8.1%. [[TCRR]] -2.4%. [[JFIN]] -2.3%. [[CENX]] -2.2%. [[GURE]] -1.8%. For further details see: KPTI, CENX, GMAB and TCRR among after-hours movers

Karyopharm Therapeutics ([[KPTI]] -0.6%) announces that the European Commission ((EC)) has granted conditional marketing authorization for NEXPOVIO (selinexor) in combination with dexamethasone for the treatment of multiple myeloma in certain patients.The approval allows for the use of the co...

Karyopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma -- NEXPOVIO is the First and Only Nuclear Ex...

KPTI has fallen 30% on earnings. COVID-19 and some increasing competition have caused lackluster growth. However, the pipeline potential does not justify a sub-$1 billion valuation. For further details see: Karyopharm Stock: Rationale For Bullishness

Karyopharm Announces Upcoming Virtual Investor Conference Participation PR Newswire NEWTON, Mass. , Feb. 17, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today a...

Karyopharm Therapeutics Inc. (KPTI) Q4 2020 Earnings Conference Call February 11, 2021 8:30 AM ET Company Participants Ian Karp - Senior Vice President, Investor and Public Relations Michael Kauffman - Chief Executive Officer Michael Mason - Chief Financial Officer John Demaree - Chief Commer...